Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: -0.05 (-1.52%)
Spread: 0.10 (3.125%)
Open: 3.30
High: 3.30
Low: 3.25
Prev. Close: 3.30
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: IS Solutions, Netservices, Plant Health Care...

Mon, 14th Sep 2009 09:51

Higher revenues helped software services group IS Solutions post broadly unchanged profits in the six months to June 30.Pre-tax profits for the period totalled £184,000, compared with £189,000 the previous year, as revenues soared to £5.12m from £3.64m. During the year, the company completed the purchase of headquarters on Sunbury on Thames and invested in establishing a branch office in the Indian sub-continent.Business communications group Netservices expects to post an operating loss of about £200,000 for the year to August 31 due to time it will take to develop relationships with clients.Depressed agricultural markets resulted in widening losses at natural plant supplement supplier Plant Health Care (PHC). Revenue in the six months to June 30 fell to $5.5m from $7.8m over the same period the previous year and pre-tax losses grew to $3.9m from $3.3m. PHC said that it had received large orders from the seed giant Monsanto for its Harpin seed treatment.China Wonder reported a drop in half year profits despite a 21% rise in sales revenue and said it continues to actively seek expansion opportunities both in the People's Republic of China and the United Kingdom. Pre-tax profit fell to £220,053 in the six month ended 30 June from £253,546 last time. Sales revenue for the period was £2.11m when compared to the £1,743,863 of sales for the same period in 2008.Expansion into Brazil and Germany helped Publishing Technologies, which provides online systems and management software to academic publishers, narrow losses sharply in the six months to June 30. Pre-tax losses totalled £99,000 for the period, compared with £299,000 for the same period the previous year. Revenue climbed to £7.7m from £7.3m.Environmental Recycling cut net losses from £1.8m to £0.54m in the half-year to June, on sales up to £427,000 (£179,000). The increasing recycling agenda has led to a considerable number of enquiries and negotiations in respect of the application of the PIM Process in various sectors, it said. The one major difficulty that remains is the ongoing litigation with the group's former CEO in Kyrgyzstan, it added.Intelligent Environments has signed a three year rolling contract with Home Retail priced on IE's transactional revenue model. IE will deliver a comprehensive electronic card statement system for Argos and Homebase store card customers.Biotech ValiRx has created a new wholly owned trading subsidiary, ValiMedix, to distribute a range of new diagnostic screening products acquired from Pasante Healthcare. The new diagnostic screening products principally comprise the Self Check screening products which allow an individual to check for potential health problems at an early stage. International Brand Licensing slipped into losses in the half year to June, losing £170,000 against a profit of £248,000. IBL said the figures should be considered against the backdrop of a very depressed sporting goods industry and a big exceptional gain last time. Timestrip, which makes labels indicating how long containers for food have been unsealed, saw higher revenues and reduced losses in the six months to June 30.. Revenues in the six months to June 30 climbed to £386m from £268m as losses narrowed to £453m from £697m.The firm also reported positive feedback from NHS trials of its TimeStripPlus technology which is used to show if a temperature sensitive product such as a drug has been exposed to incorrect temperatures.Angel Mining lost £1.5m in the 12 months ended 28 February versus £4.2m in 2008 following the reversal of impairment provisions of £3.2m linked to exploration costs at Black Angel in Greenland.The company, formerly known as Angus & Ross, wants to get Nalunaq in the south of Greenland into production this year then try and get the Black Angel mine producing by the end of 2010.Titanium Resources tumbled on Monday as it said sales fell to $19.8m in the six months ended 30 June from $32.5m previously, although some of that was due to the sale of a Bauxite mine last year.The loss after tax narrowed to $4.95m from $20.2m a year earlier as the cost of sales fell by 52% to $20.7m. 'We believe the company is on track to achieve operating profitability for H2 2009,' said boss John Sisay.Superconductor energy technology firm Zenergy Power has reported a big drop in revenue for the first half of 2009 to €0.2m from €1m and an increase in losses to £5m from £2.6m before.But it says continuing growth in its order backlog, €2.3m at the end of June, will 'smooth' its revenue recognition over reporting periods. 'However, in the short-term we expect lumpiness to be a feature of our revenue generation and this is certainly the case with our 2009 reporting.'Mobile marketing and advertising group Velti grew pre-tax profit to €2.7m in the six months to 30 June, up from €1.6m in 2008 on revenue 36% higher to €21.7m.'During the remainder of 2009 we will continue to build up momentum and grow the Company in a sustainable way with a strong focus on cash flow,' said chief executive Alex Moukas.Online retailer of ethical fashion and lifestyle products Adili saw pre-tax losses widen in the year to 30 April 2009 from £1.59m to £1.90m on sales that rose from £0.35m to £0.55m. Sales for the first five months of the current financial year are up 29% on a year earlier.The first half of 2009 saw loss before tax widen at biopharmaceutical contract manufacturer Angel Biotechnology to £0.52m from £0.46m, but revenue improved to £0.6m from £0.48m. 'Due to the structure of contracts we currently have, revenue recognition is necessarily delayed resulting in lower figures for H1 [first half] 2009 than might have been expected with the value of business signed. This situation is expected to be rectified in H2 [second half] 2009 and into 2010 as the revenues from these projects are recognised,' the company said.Security and fire alarm firm Westminster Group has won a tolling 12-month contract to provide 24-hour bodyguard protection to a rich individual and his family in the Middle East. The contract is worth £0.54m.
More News
20 Jun 2019 09:54

ValiRx secures 'substantial amendment' to VAL201 clinical trials

(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.

Read more
13 Jun 2019 11:07

ValiRx Subscription Raises GBP300,000 For Drug Trial And Development (ALLISS)

(Alliance News) - ValiRx PLC on Thursday said it raised GBP300,000 via subscription for working capital and to progress the clinical trial of its VALL201 cancer drug.Shares in ValiRx a 31%

Read more
10 Jun 2019 09:50

ValiRx In Discussions With Investor To End Subscription Agreement (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Monday confirmed it is in advanced discussions with European High Growth Opportunities SF to terminate a subscription agreement.Shares in the clinical

Read more
5 Jun 2019 10:54

ValiRx Convertible Bond Talks In Advanced Stage; Plans Open Offer (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Wednesday said it is in advanced discussions with European High Growth Opportunities SF to enter a new convertible bond facility and is planning an open in a

Read more
31 May 2019 12:04

ValiRx Extends Talks With Investor Over New Convertible Bond (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has extended the deadline to enter into a new convertible bond with European High Growth Opportunities SF to July 1.The cancer life was

Read more
29 May 2019 10:41

ValiRx Annual Loss Widens On Higher Costs And Fair Value Losses

LONDON (Alliance News) - ValiRx PLC on Wednesday reported a widened annual loss due to higher costs and losses on the fair value of financial assets.For 2018 the life sciences company, on a

Read more
29 May 2019 10:19

ValiRx losses widen as it continues to progress drug development

(Sharecast News) - Life science company ValiRx reported a loss before income tax of £4.83m in its final results on Wednesday, widening from the £3.55m loss it posted a year earlier.

Read more
2 May 2019 15:21

ValiRx Partners With Alpha Blue Ocean And Buys IP Assets Of FIT Bio

LONDON (Alliance News) - ValiRx PLC on Thursday said it has agreed to acquire the IP assets of FIT Bio for EUR5,000 and establish a genetic therapeutic and diagnostic-based joint venture with Blue

Read more
2 May 2019 09:51

ValiRx acquires IP of failed firm FIT Biotech, forms joint venture

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acquisition of the global granted patents and intellectual property assets of FIT Biotech for a nominal sum on Thursday.

Read more
26 Apr 2019 14:54

ValiRx To Raise GBP1 Million Under Deal With European High Growth (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has entered into a GBP1.3 million subscription agreement with European High Growth Opportunities SF.The stock was trading 17% lower on

Read more
26 Mar 2019 10:22

ValiRx Notes ValiSeek Co-Financing Deals For VAL401 Cancer Drug

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Tuesday said ValiSeek has secured letters of intent from two companies to co-finance the development of cancer drug VAL401.Shares a

Read more
21 Mar 2019 09:53

ValiRx Notes Encouraging Performance Of VAL201 In Cancer Trial

LONDON (Alliance News) - ValiRx PLC on Thursday said an interim inspection of its VAL201 early phase cancer trial shows the drug is performing as predicted.Shares in ValiRx were up 13% at a

Read more
21 Feb 2019 12:46

ValiRx Raises GBP500,000 Through Placing To Advance Clinical Trials (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Thursday raised GBP500,000 through a share placing to expand its clinical trial of VAL201, as well as the VAL301 and VAL101 programmes.ValiRx issued a

Read more
31 Jan 2019 13:37

ValiRx Secures Patent For VAL301 Compound In Russia And China

LONDON (Alliance News) - ValiRx PLC on Thursday said it has been granted a patent allowance for its therapeutic compound VAL301 in both Russia and China.The clinical stage biotechnology has

Read more
31 Jan 2019 10:08

ValiRx allowed patents for VAL401 in Russia and China

(Sharecast News) - Clinical-stage biotechnology company ValiRx announced on Thursday that the patent offices of Russia and China had both granted a patent allowance for its pre-clinical therapeutic compound, VAL301, subject to payment of the relevant fees.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.